Posted in Posts
Mouth cancer drug gets NICE thumbs up
The National Institute for Health and Clinical Excellence (NICE) has today issued a Final Appraisal Determination (FAD) recommending the use of cetuximab (Erbitux®) in combination with radiotherapy for the treatment of locally advanced head and neck cancer in patients for whom platinum-based chemoradiotheraphy is inappropriate. Cetuximab is the first new treatment in more than 40…